Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- In ATTR-CM, system friction is clinically meaningful because delayed or interrupted treatment changes the disease course.
- The signal isn't only which therapy gets chosen, but whether it ever becomes durable routine care.
- Because cardiovascular events accrue over time, lost exposure means lost cumulative benefit that can't be recovered later.
- Persistence is where health-system performance becomes visible to the clinician.
Why Access Delays Count as Clinical Signals
In ATTR-CM, the meaningful systems signal isn't only which disease-modifying therapy is selected, but whether treatment is actually initiated and sustained in routine care. A therapy that’s prescribed but never initiated or sustained doesn’t modify the course of a chronic, progressive cardiomyopathy. When access delays, prior-authorization requirements, pharmacy interruptions, or early discontinuation delay treatment initiation or interrupt exposure, they can affect the delivery of disease-modifying therapy and its potential benefit. These factors therefore warrant clinical attention rather than being treated as purely administrative concerns.
How Interrupted Exposure Erases Longitudinal Benefit
The benefit of disease-modifying therapy in ATTR-CM is longitudinal: it accrues through sustained exposure rather than from any single dose. Real-world adherence data in tafamidis-treated patients show that persistence is variable and worth measuring, not assumed. Exploratory recurrent-event analysis in the acoramidis ATTRibute-CM program supports a longitudinal view of cardiovascular outcomes, reinforcing the importance of sustained treatment exposure. Interruptions in treatment may reduce the opportunity to achieve the potential benefit of continued therapy. Sustained treatment exposure is therefore an integral component of the expected clinical benefit, not a secondary operational consideration.
Reading System Friction as a Treatment Variable
The broader implication is that continuity of care is integral to clinical management, not merely an operational concern. In ATTR-CM, diagnosis, access, and persistence all influence what disease-modifying therapy can realistically deliver once a patient leaves the trial setting and enters routine longitudinal management. Reading access barriers in this way connects directly to the practical management of cost and access, treatment continuity, and the importance of appropriate diagnostic confirmation.
What Clinicians Can Act on
Keeping the focus operational, the actionable signals are delayed initiation, interrupted exposure, and potential loss of treatment benefit over time. In practice, that means watching for the time from confirmed diagnosis to first dose, tracking refill gaps and authorization-driven pauses, and treating an unexplained discontinuation as a prompt to investigate rather than a closed chapter. Sustained ATTR-CM clinical management depends in part on identifying these interruptions early and addressing their underlying causes.
Frequently Asked Questions
Why treat access delays as clinical signals rather than administrative issues?
Because ATTR-CM is progressive and disease-modifying therapy depends on continued treatment, a delay or interruption can affect treatment continuity and the opportunity to achieve its potential benefit.
Why does interrupted exposure matter so much in ATTR-CM?
Treatment benefit is evaluated over time, and cardiovascular events also accrue over time, so interruptions in treatment may reduce the opportunity to achieve the potential benefit of sustained therapy. Real-world data show that treatment persistence is variable, so treatment exposure should be monitored rather than assumed.
What specific signals should a clinician track?
Clinicians should track time from confirmed diagnosis to first dose, refill gaps, authorization-driven pauses, and unexplained discontinuations. Treating each as a prompt for investigation, rather than a settled outcome, can help preserve longitudinal treatment benefit.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Access and Equity Topics
Next Clinical Step
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
- Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. Journal of the American College of Cardiology
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.